PET Imaging of mGLuR5 With Drug Challenge
What is the purpose of this trial?
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two fMRI scans, and up to three PET scans, as well as cognitive testing at each scan session. For one of the PET scans, a drug (either ketamine or n-acetyl cysteine) will be administered.
Hypothesis 1: The investigators hypothesize administration of ketamine or n-acetylcysteine (NAC) will lead to a decrease in mGluR5.
Hypothesis 2: The investigators hypothesize an improvement in memory and attentional skills after drug challenge.
Hypothesis 3: The investigators hypothesize an increase in mGluR5 availability and change in MRI measures post drug challenge as compared to baseline, signifying synaptogenesis.
Hypothesis 4: We expect there should not be a significant difference in reduction in mGluR5 availability due to differences in ABP688 radiotracer infusion.
- Ages18 - 65 years
- Trial withYale University School of Medicine
- Start Date01/04/2017
- End Date11/14/2023
- Last Updated03/06/2018
- Study HIC#1111009365